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Abstract
Background: The location of osteosarcoma in the metaphysis as well as the age of the patients
during the most rapid tumour growth suggest that factors related to skeletal growth are involved
in the pathogenesis of this tumour. In this aspect this study aims to detect somatostatin receptors
in human osteosarcomas and correlate this finding with the clinical outcome of the tumour.
Patients and methods: Immunohistochemical staining for the presence of somatostatin
receptors as well as overall survival and disease free survival rates were retrospectively studied in
twenty-nine osteosarcoma patients.
Results: Four osteosarcomas with several aggressive biologic behaviour expressed somatostatin
receptors. In these four young patients the event free rate was 0% and the overall survival rate was
50% at 4, 3 years. In contrast the event free survival rate of the twenty-five patients with negative
somatostatin receptor status was 72% with an overall survival rate of 76% at 4,3 years.
Conclusion: The present study demonstrates the existence of somatostatin receptors in human
osteosarcoma. Tumours expressing somatostatin receptors seemed to be aggressive with a very
low disease free and overall survival rate compared to osteosarcoma with negative receptor status.
Background
Osteosarcoma is the most common primary malignant
tumour of bone, with the exception of multiple myeloma.
It represents approximately 15% of all biopsy-analyzed
primary bone tumours [1,2]. It is most common in males
and occurs primarily in the second decade of life. The
most common location sites are the metaphysis of bone
[3,4]. The age of the patients, coinciding with the adoles-
cent growth spurt as well as the location of tumour sites
has led to the syllogism that factors related to skeletal
growth are involved in the pathogenesis of this tumour [5-
7]. Previous studies maintain that treatment with growth
hormone and somatostatin affects the growth of osteosa-
rcoma in animal models [8-10]. Somatostatin is believed
to exert antiproliferative effects on tumour cells through
receptor-mediated stimulation of tyrosine phosphatase
and inhibition of other endogenous growth factors, like
growth hormone and insuline-like growth factor 1
[11,12]. In this respect, the presence of somatostatin
receptors in human osteosarcoma may have a diagnostic,
prognostic and therapeutic value [13].
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In this study we aim to detect somatostatin receptors in
human osteosarcomas and correlate this finding with the
clinical outcome of the tumour.
Patients and methods
Twenty-nine patients with primary osteosarcoma who
were treated at the authors' institution between 1997 and
2006 were included in this study. Fourteen patients were
female and fifteen were male. The average age at the time
of diagnosis was 27.03 years (range 16–49 years) (Table
1). Preoperative evaluation included precision imaging
techniques (plain radiographs, computed tomography
and MRI of the lesion, computed tomography of the chest
and full body scan with Tc99m). Distribution of anatomic
tumour sites was as described in Table 1. The therapeutic
protocol included neoadjuvant chemotherapy in all
patients with high-dose methotrexate [14-16]. During
preoperative chemotherapy one patient died, while we
operated on twenty-eight patients aiming at wide resec-
tion margins.
Twenty-four patients underwent a limb salvage procedure,
while in four patients amputation was the only surgical
option in order to achieve adequate local control.
Disease-free and overall survival was recorded in all
patients (table 2).
Histological specimens were available for all patients and
were reviewed by one experienced pathologist (I.I.). The
resected specimens were sliced coronally or axially or both
to represent the largest portion of the tumour. The slices
were fixed in 10% neutral buffered formaldehyde solution
and embedded separately in paraffin. The sections were
stained with haematoxylin and eosin and were used for
immunohistochemistry. Polyclonal Rabbit Anti-Human
somatostatin was used (Dako, Denmark) [17-19] in order
to detect the presence of somatostatin receptors [20,21].
The study was approved by the Metaxa Anticancer Hospi-
tal Ethical & Scientific Committee.
Table 1: Sex, Age, Location, Surgical Treatment, Outcome and GH receptor status of 29 patients with osteosarcoma.
Sex Age Location (Site) Surgical Treatment Oncologic outcome GH receptor status
1 M 28 Thoracic Spine LSS DOD
(Died On Disease)
2 F 16 Distal femur LSS NED
(No Evident Disease)
3 F 19 Proximal Tibia Amputation DOD +
4 F 17 Proximal Tibia Amputation DOD +
5 F 39 Distal Femur LSS DOD
6 M 28 Distal Femur Amputation NED
7 M 16 Distal Fibula LSS NED
8 M 22 Distal Femur LSS DOD
9 F 18 Distal Femur LSS DOD
10 F 27 Distal Femur LSS NED
11 F 18 Distal Femur Amputation NED
12 F 35 Proximal Tibia LSS NED
13 M 16 Distal Femur LSS NED
14 M 24 Proximal Humerus LSS Disease Progression
(Pulmonary metastases)
+
15 M 18 Proximal Tibia LSS NED
16 M 32 Distal Tibia LSS NED
17 F 34 Hip Died during chemotherapy DOD
18 F 49 Proximal Tibia LSS NED
19 F 24 Distal Femur LSS NED
20 M 44 Proximal Humerus LSS DOD
21 F 39 Distal Femur LSS Disease Progression
(Local recurrence)
22 F 25 Distal Femur LSS NED
23 M 18 Distal Femur LSS NED
24 M 44 Distal Femur LSS NED
25 M 40 Distal Femur LSS NED
26 M 20 Proximal Humerus LSS NED
27 M 30 Proximal Humerus LSS NED
28 M 16 Proximal Tibia LSS Disease Progression
(Pulmonary metastases)
+
29 F 28 Proximal Tibia LSS NEDWorld Journal of Surgical Oncology 2008, 6:99 http://www.wjso.com/content/6/1/99
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Results
Somatostatin receptors were expressed in four osteosar-
coma's that exhibited aggressive features (figure 1 and 2).
These four tumours appeared in young patients (table 3)
with an aggressive biologic behaviour having an event-
free rate of 0% and an overall survival rate of 50% at 4.3
years (table 4). In contrast, the event-free survival rate of
the twenty-five patients with negative growth hormone
receptor status was 72% with an overall survival rate of
76% at 4.3 years.
Case one represents a woman, 19-years-old, with a right
proximal tibia tumour, stage II B+ on Enneking's staging
system [22]. She underwent neoadjuvant chemotherapy
followed by femoral amputation. Histological examina-
tion revealed grade II osteosarcoma with osteoblastic, as
well as chondroblastic areas and 80% tumour necrosis.
Two years later there was a local recurrence in the stump
of the sciatic nerve, which was treated with hip disarticu-
lation and chemotherapy. Four years post-operative, this
patient presented lung metastases, was treated with chem-
otherapy and eventually died after 1 year. In our retrospec-
tive histological study somatostatin receptors were
detected.
Discussion
The use of neoadjuvant chemotherapy in the treatment
protocol of osteosarcoma in the late 70's improved dis-
ease-free survival, giving a cure rate of 60%–70% for
patients with nonmetastatic osteosarcoma of the extremi-
ties at presentation [23-25].
Little is known about the aetiology and pathogenesis of
this tumour. Genetic predisposition, viral aetiology, irra-
diation and alkylating agents have been suggested in the
pathogenesis of osteosarcoma [3,26,27]. Nowadays,
molecular biology seems to be the next step in under-
standing pathogenesis and improving survival of osteosa-
rcoma. Tumour location in the metaphysis as well as the
age of the patients coinciding with the period of rapid
body growth suggest that factors related to skeletal growth
are involved in the pathogenesis of this tumour.
Table 3: Mean Age of patients with positive staining vs. patients 
with negative staining for receptors of Growth Hormone.
Patients with Positive 
staining for receptors of 
Growth Hormone
Patients with Negative 
staining for receptors of 
Growth Hormone
AGE 
(MEAN/RANGE)
19/16–24 years 28,32/16–49 years
Osteosarcoma somatostatin negative. Magnification ×400 Figure 1
Osteosarcoma somatostatin negative. Magnification 
×400. This case of an osteosarcoma had no somatostatin 
receptors. Immunohistochemistry staining with somatostatin 
did not produce any reaction.
Table 2: Disease free and overall survival rate at 4, 48 years, in 29 
patients with osteosarcoma.
Frequency Percent
NED
(No Evident Disease)
18 62,0
Disease progression 3 10,4
DOD
(Died On Disease)
82 7 , 6
Total 29 100,0
Osteosarcoma somatostatin positive. Magnification ×630 Figure 2
Osteosarcoma somatostatin positive. Magnification 
×630. In this case staining with somatostatin produced a 
reaction appearing with an orange zone around the nuclei. 
This case of osteosarcoma is expressing somatostatin recep-
tors.World Journal of Surgical Oncology 2008, 6:99 http://www.wjso.com/content/6/1/99
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Somatostatin is characterized as a hormone which inhib-
its the release of growth hormone from the anterior pitui-
tary gland [28]. The present study demonstrates the
existence of somatostatin receptors in human osteosar-
coma. Further research is necessary to demonstrate the
importance of this finding and its clinical relevance, since
there is also evidence from animal studies that treatment
with growth hormone and somatostatin affects the
growth of osteosarcoma in animal models [8-10]. There is
also one study in pediatric patients having metastatic oste-
osarcoma treated with somatostatin analogue (OncoLar)
which shows that the levels of Insulin-like growth factor-
1 were reduced. However, this study did not yield signifi-
cant clinical results [29].
To our knowledge, there is only one study on humans in
the literature with 18 osteosarcoma patients where the
authors investigated somatostatin receptors by virtue of
scintigraphy. In this study a very high incidence of
patients with somatostatin receptors was found (up to
75%). The authors found higher incidence in non-meta-
static patients and concluded that there is a possible rela-
tion between the somatostatin receptors presence and the
biological behaviour of the tumour. [30]
A limitation to our study is the small number of speci-
mens that were analyzed, which makes statistical analysis
unfeasible; however, because of the novelty of our study
and since the tumours expressing somatostatin receptors
had a more deleterious course with a very low disease-free
and overall survival rate compared to osteosarcoma with
negative receptor status, even though the percentage
(14%) was much lower than that in the Rizzoli study [30],
we believe that this finding should be thoroughly evalu-
ated and investigated with further studies.
Conclusion
In this study we detected somatostatin receptors in human
osteosarcomas. This finding seems to have a prognostic
value, predicating a severe aggressive biologic behaviour
of the tumour as well as possible therapeutic implications.
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